• Online Features  This Article  • Full text  • PDF  • eFigure  • CME Course for This Article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (60)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Statistics and Research Methods  • Review  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants

Kausik K. Ray, MD, MPhil, FACC, FESC; Sreenivasa Rao Kondapally Seshasai, MD, MPhil; Sebhat Erqou, MD, MPhil, PhD; Peter Sever, PhD, FRCP, FESC; J. Wouter Jukema, MD, PhD; Ian Ford, PhD; Naveed Sattar, FRCPath

Arch Intern Med. 2010;170(12):1024-1031.

Background  Statins have been shown to reduce the risk of all-cause mortality among individuals with clinical history of coronary heart disease. However, it remains uncertain whether statins have similar mortality benefit in a high-risk primary prevention setting. Notably, all systematic reviews to date included trials that in part incorporated participants with prior cardiovascular disease (CVD) at baseline. Our objective was to reliably determine if statin therapy reduces all-cause mortality among intermediate to high-risk individuals without a history of CVD.

Data Sources  Trials were identified through computerized literature searches of MEDLINE and Cochrane databases (January 1970-May 2009) using terms related to statins, clinical trials, and cardiovascular end points and through bibliographies of retrieved studies.

Study Selection  Prospective, randomized controlled trials of statin therapy performed in individuals free from CVD at baseline and that reported details, or could supply data, on all-cause mortality.

Data Extraction  Relevant data including the number of patients randomized, mean duration of follow-up, and the number of incident deaths were obtained from the principal publication or by correspondence with the investigators.

Data Synthesis  Data were combined from 11 studies and effect estimates were pooled using a random-effects model meta-analysis, with heterogeneity assessed with the I² statistic. Data were available on 65 229 participants followed for approximately 244 000 person-years, during which 2793 deaths occurred. The use of statins in this high-risk primary prevention setting was not associated with a statistically significant reduction (risk ratio, 0.91; 95% confidence interval, 0.83-1.01) in the risk of all-cause mortality. There was no statistical evidence of heterogeneity among studies (I² = 23%; 95% confidence interval, 0%-61% [P = .23]).

Conclusion  This literature-based meta-analysis did not find evidence for the benefit of statin therapy on all-cause mortality in a high-risk primary prevention set-up.

Author Affiliations: Department of Public Health and Primary Care, University of Cambridge, Cambridge, England (Drs Ray, Seshasai, and Erqou); Department of Cardiology, Addenbrooke's Hospital, Cambridge (Dr Ray); Department of Clinical Pharmacology and Therapeutics, Imperial College, and National Heart and Lung Institute, London, England (Dr Sever); Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands (Dr Jukema); and Department of Statistics (Dr Ford) and BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine (Dr Sattar), University of Glasgow, Glasgow, Scotland.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Primary Prevention Cardiovascular Disease: Better Than Drugs
John J. Pippin
Arch Intern Med. 2010;170(20):1860-1861.
EXTRACT | FULL TEXT  

Statins and All-Cause Mortality in High-Risk Primary Prevention of Patients With Cardiovascular Risk Factors
Jasper Jan Brugts and Jaap W. Deckers
Arch Intern Med. 2010;170(22):2041.
EXTRACT | FULL TEXT  

Statins and All-Cause Mortality in High-Risk Primary Prevention: A Second Look at the Results
Gabriel Chodick and Varda Shalev
Arch Intern Med. 2010;170(22):2041-2042.
EXTRACT | FULL TEXT  

Are Statins Effective in High-Risk Primary Prevention?
Francesco Dentali and Luigina Guasti
Arch Intern Med. 2010;170(22):2042-2043.
EXTRACT | FULL TEXT  

Are Statins Effective in High-Risk Primary Prevention?—Reply
Kausik K. Ray, Sreenivasa Rao Kondapally Seshasai, Wouter Jukema, and Naveed Sattar
Arch Intern Med. 2010;170(22):2043-2044.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Cholesterol-Lowering Therapy for Primary Prevention: Still Much We Don't Know
Lee A. Green
Arch Intern Med. 2010;170(12):1007-1008.
EXTRACT | FULL TEXT  

Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy: A Critical Reappraisal
Michel de Lorgeril, Patricia Salen, John Abramson, Sylvie Dodin, Tomohito Hamazaki, Willy Kostucki, Harumi Okuyama, Bruno Pavy, and Mikael Rabaeus
Arch Intern Med. 2010;170(12):1032-1036.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins
Danaei et al.
Am J Epidemiol 2012;175:250-262.
ABSTRACT | FULL TEXT  

Comment on 'The great cholesterol myth: unfortunate consequences of Brown and Goldstein's mistake'
Miller
QJM 2011;0:hcr250v1-hcr250.
FULL TEXT  

The Cardiovascular Biomarker Conundrum: Challenges and Solutions
Prasad and Bonow
JAMA 2011;306:2151-2152.
FULL TEXT  

The efficacy and cost-effectiveness of statins in low-risk patients
Gupta
CMAJ 2011;183:1821-1823.
FULL TEXT  

Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis
Tonelli et al.
CMAJ 2011;183:E1189-E1202.
ABSTRACT | FULL TEXT  

Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
Conly et al.
CMAJ 2011;183:E1180-E1188.
ABSTRACT | FULL TEXT  

The great cholesterol myth; unfortunate consequences of Brown and Goldstein's mistake
Adams
QJM 2011;104:867-870.
ABSTRACT | FULL TEXT  

Making the Case for Selective Use of Statins in the Primary Prevention Setting
Minder et al.
Arch Intern Med 2011;171:1593-1594.
FULL TEXT  

Reply
Erbel et al.
J Am Coll Cardiol 2011;58:1081-1083.
FULL TEXT  

Value of Primordial and Primary Prevention for Cardiovascular Disease: A Policy Statement From the American Heart Association
Weintraub et al.
Circulation 2011;124:967-990.
ABSTRACT | FULL TEXT  

Continuous Positive Airway Pressure Reduces Postprandial Lipidemia in Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Crossover Trial
Phillips et al.
Am. J. Respir. Crit. Care Med. 2011;184:355-361.
ABSTRACT | FULL TEXT  

Misinformation in the medical literature: What role do error and fraud play?
Steen
J. Med. Ethics 2011;37:498-503.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era
Lazar et al.
Circulation 2011;124:146-153.
ABSTRACT | FULL TEXT  

Clinical Inertia as a Clinical Safeguard
Giugliano and Esposito
JAMA 2011;305:1591-1592.
FULL TEXT  

Update in Cardiology: Evidence Published in 2010
Redberg
ANN INTERN MED 2011;154:549-553.
FULL TEXT  

Practical use of the Framingham risk score in primary prevention: Canadian perspective
Bosomworth
cfp 2011;57:417-423.
ABSTRACT | FULL TEXT  

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis
Greving et al.
BMJ 2011;342:d1672-d1672.
ABSTRACT | FULL TEXT  

Statins for primary prevention of cardiovascular disease
Deckers and Blumenthal
BMJ 2011;342:d1048-d1048.
FULL TEXT  

The Cost-Effectiveness of Rosuvastatin Therapy: JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Hlatky
J Am Coll Cardiol 2011;57:792-793.
FULL TEXT  

Statins are not associated with a decrease in all cause mortality in a high-risk primary prevention setting
Kaess and Vasan
Evid. Based Med. 2011;16:8-9.
FULL TEXT  

Bad medicine: general practice
Spence
BMJ 2010;341:c7336-c7336.
FULL TEXT  

Statins and All-Cause Mortality in High-Risk Primary Prevention of Patients With Cardiovascular Risk Factors
Brugts and Deckers
Arch Intern Med 2010;170:2041-2041.
FULL TEXT  

Trials by Independent Expert Bodies
Breimer and Mikhailidis
Arch Intern Med 2010;170:2042-2042.
FULL TEXT  

Are Statins Effective in High-Risk Primary Prevention?--Reply
Ray et al.
Arch Intern Med 2010;170:2043-2044.
FULL TEXT  

Statins and All-Cause Mortality in High-Risk Primary Prevention: A Second Look at the Results
Chodick and Shalev
Arch Intern Med 2010;170:2041-2042.
FULL TEXT  

Are Statins Effective in High-Risk Primary Prevention?
Dentali and Guasti
Arch Intern Med 2010;170:2042-2043.
FULL TEXT  

Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database
Hippisley-Cox et al.
BMJ 2010;341:c6624-c6624.
ABSTRACT | FULL TEXT  

Primary Prevention Cardiovascular Disease: Better Than Drugs
Pippin
Arch Intern Med 2010;170:1860-1861.
FULL TEXT  

CardioPulse Articles * Focused Update of the ESC Guidelines on device therapy in heart failure * ESC recommendations for individual certification and institutional cardiovascular magnetic resonance accreditation, in Europe * The final, Climbing the academic ladder in cardiology: USA * There are two different career tracks for academic medicine in the USA * Company success: Genzyme * Genzyme's research in cardiovascular disease, putting rare conditions on centre stage * Towards individualized preventive therapy
Eur Heart J 2010;31:2559-2566.
FULL TEXT  

JUPITER seems to be bypassed
Murray
BMJ 2010;341:c5835-c5835.
FULL TEXT  

Author's reply
Hayward
BMJ 2010;341:c5837-c5837.
FULL TEXT  

Statins and Primary Prevention for Patients at High Risk for Heart Disease
JWatch General 2010;2010:3-3.
FULL TEXT  

Cholesterol-Lowering Therapy for Primary Prevention: Still Much We Don't Know
Green
Arch Intern Med 2010;170:1007-1008.
FULL TEXT